CLASS II Device recall · Reported 6 Mar 2013 · FDA Enforcement Report

Atrapro Antipruritic Hydrogel gel tube recalled

Oculus Innovative Sciences is recalling Atrapro Antipruritic Hydrogel gel tube, 4, distributed nationwide in the US. The recall was initiated on 12 Feb 2013 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 12A0012, Exp 2/2013; Lot 12A0013, Exp 2/2013: Lot 12A1116, Exp 2.2013; Lot 12A1119, Exp 2/2013; Lot 12B1144, Exp 3/2013; Lot 12B1148, Exp 3/2013; Lot 12C1157, Exp 4/2013; Lot 12E190. Exp 6/2013; Lot 12E194, Exp 6/2013; Lot 12E198, Exp 6/2013; Lot 12E202. Exp 6/2013; Lot 12E208, Exp 6/2013; Lot 12E211, Exp 6/2013.
Quantity recalled56,566 1.5 oz tubes

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0890-2013
FDA event ID
64316
Recalling firm
Oculus Innovative Sciences, Petaluma, CA
Classification
Class II
Status
Terminated
Recall initiated
12 Feb 2013
FDA classified
26 Feb 2013
Reported
6 Mar 2013
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

12 Feb 2013Recall initiated by company
26 Feb 2013Classified by FDA+14 days
6 Mar 2013Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Out of specification result - stability test failure of free available chlorine (FAC) which functions as a preservative for the hydrogel. The 13 month test result obtained was 4 ppm FAC and the stability specification is >10 ppm FAC.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Atrapro Antipruritic Hydrogel, 1.5 oz gel tube, 4 Net wt/ 1.5 oz.. RX only, Professional Sample, Not for Sale. Pre-printed tube: MS31071, Shelf carton: PL51091-08 Atrapro Antipruritic HydroGel is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis.

Where it was distributed

Nationwide Distribution - One distributor in PA

Nationwide Pennsylvania

Questions about this recall

Why was it recalled?

Out of specification result - stability test failure of free available chlorine (FAC) which functions as a preservative for the hydrogel. The 13 month test result obtained was 4 ppm FAC and the stability specification is >10 ppm FAC.

Which lots are affected?

Lot 12A0012, Exp 2/2013; Lot 12A0013, Exp 2/2013: Lot 12A1116, Exp 2.2013; Lot 12A1119, Exp 2/2013; Lot 12B1144, Exp 3/2013; Lot 12B1148, Exp 3/2013; Lot 12C1157, Exp 4/2013; Lot 12E190. Exp 6/2013; Lot 12E194, Exp 6/2013; Lot 12E198, Exp 6/2013; Lot 12E202. Exp 6/2013; Lot 12E208, Exp 6/2013; Lot 12E211, Exp 6/2013.

Where was it sold?

Nationwide Distribution - One distributor in PA

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Oculus Innovative Sciences

All 2
ReportedClassRecallCompanyReasonWhere
DeviceCLASS IICeramax Skin Barrier Cream recalled by Oculus Innovative SciencesOculus Innovative SciencesPotency & AssayNationwide

Other Other Medical Devices recalls

All 13,778